GlassScriptPhysician profile
Daniel L Sambursky
NPI 1245271931
$4,593.46
in general payments reported to CMS, 2019-2025
19 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $899 · 2020: $499 · 2021: $747 · 2022: $474 · 2023: $608 · 2024: $818 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,936 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.77 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $3,205.14 | 2019-2025 | Clareon, Lensx, Clareon Panoptix Pro |
| Johnson & Johnson Surgical Vision, INC. | $397.78 | 2020-2024 | Catalys System, Tecnis Iol, Tecnis Iol |
| Glaukos Corporation | $388.13 | 2021-2025 | Idose, Idosetr |
| Ocular Therapeutix, INC. | $88.21 | 2021-2025 | Dextenza |
| Kala Pharmaceuticals, INC. | $75.83 | 2021 | |
| Allergan, INC. | $69.49 | 2019-2021 | |
| Rxsight INC | $60.60 | 2022-2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens |
| Omeros Corporation | $52.60 | 2019-2021 | |
| Oyster Point Pharma, INC. | $43.17 | 2024 | Tyrvaya, Ryzumvi |
| New World Medical,INC. | $39.36 | 2023-2024 | Ahmed Glaucoma Valve, Streamline, Clearpath |
| Rayner Intraocular Lenses Limited | $30.21 | 2022 | |
| Sight Sciences, INC. | $27.43 | 2021 | |
| Biotissue Holdings INC. | $23.04 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $21.62 | 2024 | Envista Mx60 Iol |
| Tarsus Pharmaceuticals, INC. | $21.19 | 2024 | Xdemvy |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $18.86 | 2021 | |
| Sun Pharmaceutical Industries INC. | $16.51 | 2021 | |
| Dompe US, INC. | $14.29 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$639,549.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Sambursky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.